HERCULES, CA –April 1, 2009 – Bio-Rad Laboratories, Inc, (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of the SsoFast™ EvaGreen® Supermix, the first member of Bio-Rad’s next-generation family of high-performance, real-time PCR reagents.

Through instant polymerase activation, optimal primer binding, and rapid polymerization kinetics, the supermix enables qPCR cycling protocols to be completed in less than 30 minutes. Currently available products take 40 minutes or more to complete the same protocols.

“Offering qPCR results in less than 30 minutes, SsoFast EvaGreen Supermix represents up to a 25% improvement compared to other currently available fast qPCR mixes,” said Viresh Patel, Senior Product Manager, PCR Reagents.

Not only does the supermix deliver results in less time, the unique combination of Bio?Rad’s patented hot-start Sso7d fusion protein technology, optimized buffer and EvaGreen dye increases the product’s reliability and sensitivity. Such reproducibility enables efficient and accurate quantification of gene targets over a very broad range of expression levels.

The use of EvaGreen dye results in less PCR inhibition and greater reliability in High Resolution Melt (HRM) analysis for genotyping studies. Minimizing PCR inhibition also ensures maximum PCR efficiency, sensitivity and reproducibility. Additionally, EvaGreen generates higher fluorescence signals and increases the accuracy of melt curve analysis, making it a superior choice for HRM.

The robust performance and characteristics of SsoFast EvaGreen Supermix are enhanced when used with Bio-Rad’s CFX96 Real-Time PCR System. The superior thermal uniformity and detection capabilities of the instrument take full advantage of the fast enzyme and optimized formulation used in the supermix to deliver fast, superior qPCR results.

For more information about SsoFast EvaGreen Supermix, visit us on the Web at

www.bio-rad.com/supermixes/.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.